Evidence map›Paper›PMID 32459958›Full record

ArticleBiochemistry2020

Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA.

Angelica V Medina-Cucurella, Gary F Bammert, William Dunkle, Christopher Javens, Yaqi Zhu, Veronica T Mutchler, Janet T Teel, Caitlin A Stein, Steve A Dunham, Timothy A Whitehead

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Angelica V Medina-CucurellaDepartment of Chemical Engineering and Materials Science, Michigan State University, Engineering Building, 428 South Shaw Lane, Room 2100, East Lansing, Michigan 48824, United States.
Gary F BammertVeterinary Medicine Research and Development, Zoetis Global Therapeutic Research, 333 Portage Street, Kalamazoo, Michigan 49007, United States.
William DunkleVeterinary Medicine Research and Development, Zoetis Global Therapeutic Research, 333 Portage Street, Kalamazoo, Michigan 49007, United States.
Christopher JavensVeterinary Medicine Research and Development, Zoetis Global Therapeutic Research, 333 Portage Street, Kalamazoo, Michigan 49007, United States.
Yaqi ZhuVeterinary Medicine Research and Development, Zoetis Global Therapeutic Research, 333 Portage Street, Kalamazoo, Michigan 49007, United States.
Veronica T MutchlerVeterinary Medicine Research and Development, Zoetis Global Therapeutic Research, 333 Portage Street, Kalamazoo, Michigan 49007, United States.
Janet T TeelVeterinary Medicine Research and Development, Zoetis Global Therapeutic Research, 333 Portage Street, Kalamazoo, Michigan 49007, United States.
Caitlin A SteinDepartment of Chemical Engineering and Materials Science, Michigan State University, Engineering Building, 428 South Shaw Lane, Room 2100, East Lansing, Michigan 48824, United States.
Steve A DunhamVeterinary Medicine Research and Development, Zoetis Global Therapeutic Research, 333 Portage Street, Kalamazoo, Michigan 49007, United States.
Timothy A WhiteheadDepartment of Chemical Engineering and Materials Science, Michigan State University, Engineering Building, 428 South Shaw Lane, Room 2100, East Lansing, Michigan 48824, United States.ORCID 0000-0003-3177-1361
Zoetis (United States) · USMichigan State University · USUniversity of Colorado Boulder · US

Funding

Plant Biotechnology for Health and SustainabilityT32GM110523 · NIGMS · MICHIGAN STATE UNIVERSITY · PI LAST, ROBERT LOUIS · 2014 to 2023
$2.2M
NIGMS NIH HHS T32 GM110523
6 · The paper itself

Abstract

Interleukin-31 (IL-31) is a major protein involved in severe inflammatory skin disorders. Its signaling pathway is mediated through two type I cytokine receptors, IL-31RA (also known as the gp130-like receptor) and the oncostatin M receptor (OSMR). Understanding molecular details in these interactions would be helpful for developing antagonist anti-IL-31 monoclonal antibodies (mAbs) as potential therapies. Previous studies suggest that human IL-31 binds to IL-31RA and then recruits OSMR to form a ternary complex. In this model, OSMR cannot interact with IL-31 in the absence of IL-31RA. In this work, we show that feline IL-31 (fIL-31) binds independently with feline OSMR using surface plasmon resonance, an enzyme-linked immunosorbent assay, and yeast surface display. Moreover, competition experiments suggest that OSMR shares a partially overlapping epitope with IL-31RA. We then used deep mutational scanning to map the binding sites of both receptors on fIL-31. In agreement with previous studies of the human homologue, the binding site for IL31-RA contains fIL-31 positions E20 and K82, while the binding site for OSMR comprises the "PADNFERK" motif (P103-K110) and position G38. However, our results also revealed a new overlapping site, composed of positions R69, R72, P73, D76, D81, and E97, between both receptors that we called the "shared site". The conformational epitope of an anti-feline IL-31 mAb that inhibits both OSMR and IL-31RA also mapped to this shared site. Combined, our results show that fIL-31 binds IL-31RA and OSMR independently through a partially shared epitope. These results suggest reexamination of the putative canonical mechanisms for IL-31 signaling in higher animals.

Indexed as

AnimalsCatsEpitopesHumansInterleukinsModels, MolecularOncostatin M Receptor beta SubunitReceptors, InterleukinEpitopesInterleukinsOncostatin M Receptor beta SubunitReceptors, Interleukin

Identifiers

PMID32459958
PMCPMC7379511
OpenAlexW3028713566

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.